Compare · ABT vs AMRX
ABT vs AMRX
Side-by-side comparison of Abbott Laboratories (ABT) and Amneal Pharmaceuticals Inc. (AMRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AMRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 278.1x AMRX ($651.3M).
- Over the past year, ABT is down 19.0% and AMRX is up 87.6% - AMRX leads by 106.6 points.
- ABT has been more active in the news (11 items in the past 4 weeks vs 1 for AMRX).
- ABT has more recent analyst coverage (25 ratings vs 7 for AMRX).
- Company
- Abbott Laboratories
- Amneal Pharmaceuticals Inc.
- Price
- $104.88+0.16%
- $19.18-0.31%
- Market cap
- $181.14B
- $651.3M
- 1M return
- +2.58%
- +4.78%
- 1Y return
- -19.02%
- +87.62%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 1
- Recent ratings
- 25
- 7
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest AMRX
- Amneal to Report Third Quarter 2026 Results on November 3, 2026
- Oppenheimer initiated coverage on Amneal Pharmaceuticals with a new price target
- Director Buchi J Kevin gifted 20,445 shares (SEC Form 4)
- Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Director Buchi J Kevin exercised 20,445 shares at a strike of $14.45, increasing direct ownership by 27% to 95,522 units (SEC Form 4)
- Leerink Partners initiated coverage on Amneal Pharmaceuticals with a new price target
- SEC Form S-3ASR filed by Amneal Pharmaceuticals Inc.
- Executive Vice President Boyer Andrew S gifted 80,000 shares, decreasing direct ownership by 29% to 193,646 units (SEC Form 4)
- Executive Vice President Boyer Andrew S gifted 152,426 shares, decreasing direct ownership by 36% to 273,646 units (SEC Form 4)
- Director Kiely John sold $882,000 worth of shares (50,000 units at $17.64) and gifted 10,000 shares, decreasing direct ownership by 23% to 200,252 units (SEC Form 4)